Abstract 413P
Background
In Asia, ∼40% of patients (pts) with non-small cell lung cancer (NSCLC) are epidermal growth factor receptor-mutation (EGFRm) positive. T790M mutation occurs in ∼50% of pts who develop resistance to a first-/second-generation (1G/2G) EGFR-tyrosine kinase inhibitor (TKI). To investigate prevailing treatment patterns and T790M testing practices in pts with EGFRm locally advanced/metastatic NSCLC treated with first-line (1L) 1G/2G EGFR-TKI, real-world (RW) data were obtained from pts in South Korea.
Methods
Retrospective, non-interventional medical record review of pts with EGFRm NSCLC treated with 1L 1G/2G EGFR-TKIs in routine practice settings between 1 Jan 2015–31 Dec 2017 (follow up: end 2019). Study endpoints: demographic/disease characteristics, 1L EGFR-TKI therapy selection, T790M mutation testing and second-line (2L) therapy selection.
Results
235 pts were included: median age 70 (40–93) years, 63% female, and 64% never smoked. At initial NSCLC diagnosis, 89% of pts had metastatic disease, 63% had an ECOG PS score of 0/1; 57% were ex19del positive. 1L 1G/2G EGFR-TKI therapy: 45% afatinib; 43% gefitinib; 13% erlotinib. 164/235 pts (70%) progressed on 1L therapy; median treatment duration of 10.3 months (mo; range: 0.1–37.2). 71/235 pts (30%) did not progress: 37 (16%) remained on 1L therapy and 34 (14%) discontinued 1L therapy before end of follow-up. 22/235 (9%) died during/after 1L therapy without receiving 2L therapy. Following progression, 68% (n=111/164) were tested for T790M, 43% (n=48/111) were T790M positive; 88% (n=42/48) of those received osimertinib. Overall, 120/164 (73%) received 2L therapy – mainly pemetrexed (n=49; 41%).
Conclusions
In this study, of pts who progressed on 1L 1G/2G EGFR-TKI, 27% did not receive 2L therapy, while only 68% were T790M tested; 88% of positive pts received osimertinib. Suboptimal rates of mutation testing and use of recommended 2L therapies may reflect the fact osimertinib was not reimbursed in South Korea until Dec 2017.
Clinical trial identification
Editorial acknowledgement
Louise Prince, PhD of Ashfield Healthcare Communications, part of UDG Healthcare plc, who provided medical writing support funded by AstraZeneca, Cambridge, UK, the manufacturer of osimertinib, in accordance with Good Publications Practice (GPP3) guidelines.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
Y-C. Kim: Honoraria (institution), Research grant/Funding (self): AstraZeneca; Honoraria (self), Research grant/Funding (self): Roche; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim. K. Davis: Research grant/Funding (institution), Full/Part-time employment, Employee of RTI Health Solutions, which has received contract research funding from AstraZeneca for my participation in the conduct of the currently submitted study/abstract: RTI Health Solutions; Research grant/Funding (self): Novartis; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Vertex; Research grant/Funding (self): Eli Lilly; Research grant/Funding (self): Eisai. S.P. Nagar: Full/Part-time employment: RTI Health Solutions. W. Sawyer: Full/Part-time employment, I am an independent statistical contractor working for AstraZeneca. N. Yu: Full/Part-time employment: AstraZeneca. A. Taylor: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session